|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Factor Xa-inhibitor apixaban is an oral anticoagulant prescribed in atrial fibrillation (AF) for stroke prevention.
|
31564018 |
2020 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), 19,679 patients with atrial fibrillation and hypertension were categorized according to average systolic blood pressure (SBP) and diastolic blood pressure (DBP).
|
31352829 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the "dabigatran bridge" group, the activated partial thromboplastin time was significantly longer, and coagulation markers (soluble fibrin monomer and thrombin-antithrombin complexes) were significantly lower than in the interrupted group before ablation.The "dabigatran bridge" seems to be a reasonable anticoagulation protocol to minimize the thromboembolic risk while ensuring safety in patients undergoing AF ablation and taking factor Xa inhibitors.
|
31735780 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a prospective echocardiographic substudy of the Effective Anticoagulation with Factor Xa Next Generation in AF-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) study, 971 patients underwent transthoracic echocardiography.
|
31777160 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF).
|
30976787 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we analyze bleeding outcomes according to the ISTH (International Society on Thrombosis and Hemostasis), TIMI (Thrombolysis in Myocardial Infarction), GUSTO (Global Usage of Strategies to Open Occluded Arteries), and BARC (Bleeding Academic Research Consortium) bleeding scales in the ENGAGE AF (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation)-TIMI 48 trial (NCT00781391) of edoxaban versus warfarin.
|
31597460 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Event rates will be compared with event rates reported in the PREvention oF thromboembolic events-European Registry in Atrial Fibrillation in atrial fibrillation (PREFER in AF) and PREFER in AF Prolongation registries, and in the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction 48 study datasets.
|
30540648 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rivaroxaban is a directly acting oral anticoagulant (DOAC) that inhibits factor Xa and is widely used for stroke prevention in patients with non-valvular atrial fibrillation (AFib).
|
31263649 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) was a multinational randomized trial of the oral factor Xa inhibitor edoxaban in patients with atrial fibrillation and a CHADS<sub>2</sub> score ≥2.
|
30586727 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction Study 48) was a randomized, double-blind trial comparing edoxaban with warfarin in patients with AF followed for 2.8 years.
|
31296289 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relative efficacy and safety profile of the oral Factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation and established coronary artery disease (CAD) has not been analyzed.
|
30039978 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation.
|
31236790 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Coagulation factor Xa activates the protease-activated receptor 2 (PAR2) and causes tissue fibrosis; however, the effects of Xa inhibitor edoxaban on atrial fibrosis and atrial fibrillation (AF) have not been investigated.
|
30874892 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the NOACs, apixaban - a very specific antagonist of activated factor Xa - has pharmacokinetic and pharmacodynamic properties that allow significant efficacy in AF management.
|
29034832 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Edoxaban, a direct factor Xa inhibitor, is noninferior vs warfarin for the prevention of stroke or systemic embolism with less major bleeding in patients with nonvalvular AF.
|
29663464 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Edoxaban is an orally active, direct factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation and for the treatment of venous thromboembolism.
|
28512699 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background and Purpose- Edoxaban is a direct oral factor Xa inhibitor with proven efficacy and safety among patients with atrial fibrillation.
|
30355093 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction) compared higher-dose edoxaban regimen (HD-ER) and lower-dose edoxaban regimen with well-managed warfarin in 21 105 patients with atrial fibrillation.
|
29748353 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, Factor Xa inhibitors reduce PV spontaneous activities and may modulate occurrence of atrial fibrillation by inhibiting PAR1 and reducing the I<sub>Na-late</sub> in PVs.
|
30017860 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
The randomised controlled phase IIIb AXADIA-AFNET 8 trial will evaluate the safety and efficacy of the factor Xa inhibitor apixaban in patients with AF requiring haemodialysis.
|
30206088 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, further studies are needed to further define the efficacy and safety of performing AF ablation with uninterrupted factor XA inhibitors or direct thrombin inhibitors.Methods and Results:We have performed CA of AF without discontinuation of either VKA or DOAC therapy since April 2014.
|
29657252 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
The global ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial compared the efficacy and safety of edoxaban versus warfarin over a median follow-up of 2.8 years.
|
30236308 |
2018 |
|
Atrial Fibrillation
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
|
29538002 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
We included randomised controlled trials (RCTs) that directly compared the effects of long-term treatment (lasting more than four weeks) with factor Xa inhibitors versus VKAs for preventing cerebral and systemic embolism in people with AF.
|
29509959 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Factor Xa (FXa) inhibitors, used for stroke prevention in atrial fibrillation and venous thromboembolism treatment and prevention, are the dominant non-Vitamin K oral anticoagulants on the market.
|
28843518 |
2018 |